Immunomodulation of Myasthenia Gravis Associated Autoimmune Responses by an Altered Peptide Ligand: Mechanisms of action
作者： Miri Pass-Rozner , Anat Faber-Elmann , Michael Sela , Edna Mozes
DOI: 10.1007/978-94-011-4060-7_17
关键词: Experimental autoimmune encephalomyelitis 、 Acetylcholine receptor 、 Immunology 、 Chemistry 、 Inositol phosphate 、 Lymphocyte 、 Myasthenia gravis 、 Immune system 、 Peptide ligand 、 Nicotinic acetylcholine receptor
摘要: Myasthenia gravis (MG) and its experimental animal model, autoimmune myasthenia (EAMG), are immune disorders characterized by circulating antibodies lymphocyte autoreactivity to nicotinic acetylcholine receptor (AChR). Although the production of specific is directly attributed B cells, there extensive evidence that T cells have a key role in etiopathology disease humans animals [1-4]. Since α-subunit AChR was shown be predominant for cell epitopes [2], we used peptides representing different sequences human study initiation, development immunomodulation gravis.
springer.com
sci-hub.st 参考文章(30)
Balaji Balasa, Nora Sarvetnick, Premkumar Christadoss, Caishu Deng, Jae Lee, The Th2 Cytokine IL-4 Is Not Required for the Progression of Antibody-Dependent Autoimmune Myasthenia Gravis Journal of Immunology. ,vol. 161, pp. 2856- 2862 ,(1998)
K S Picha, M K Kennedy, D S Torrance, K M Mohler, Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. Journal of Immunology. ,vol. 149, pp. 2496- 2505 ,(1992)
Zeng-Yu Wang, Jian Qiao, Hasn Link, Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. Journal of Neuroimmunology. ,vol. 44, pp. 209- 214 ,(1993) , 10.1016/0165-5728(93)90045-Z
R. Ahlberg, Q. Yi, R. Pirskanen, G. Matell, C. Swerup, E. P. Rieber, G. Riethmuller, G. Holm, A. K. Lefvert, Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology. ,vol. 44, pp. 1732- 1737 ,(1994) , 10.1212/WNL.44.9.1732
F.-D. SHI, G.-X. ZHANG, X.-F. BAI, P.-H. VAN DER MEIDE, H. LINK, Cellular mRNA expression of interferon-gamma (IFN-γ), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats Clinical and Experimental Immunology. ,vol. 108, pp. 523- 528 ,(1997) , 10.1046/J.1365-2249.1997.3881284.X
Roland S. Liblau, Steven M. Singer, Hugh O. McDevitt, Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases Immunology Today. ,vol. 16, pp. 34- 38 ,(1995) , 10.1016/0167-5699(95)80068-9
Andrew C Chan, Andrey S Shaw, Regulation of antigen receptor signal transduction by protein tyrosine kinases Current Opinion in Immunology. ,vol. 8, pp. 394- 401 ,(1996) , 10.1016/S0952-7915(96)80130-0
S J Khoury, W W Hancock, H L Weiner, Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. Journal of Experimental Medicine. ,vol. 176, pp. 1355- 1364 ,(1992) , 10.1084/JEM.176.5.1355
A. Faber-Elmann, M. Paas-Rozner, M. Sela, E. Mozes, Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 14320- 14325 ,(1998) , 10.1073/PNAS.95.24.14320
Brian D. Evavold, Joanne Sloan-Lancaster, Paul M. Allen, Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands Immunology Today. ,vol. 14, pp. 602- 609 ,(1993) , 10.1016/0167-5699(93)90200-5